Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome.

BMC ophthalmology - 11 Apr 2015

Beykin Gala, Grunin Michelle, Averbukh Edward, Banin Eyal, Hemo Yitzchak, Chowers Itay

Abstract excerpt

BACKGROUND: To evaluate the long-term outcome of bevacizumab therapy for neovascular age related macular degeneration (NVAMD) in the setting of a clinic. METHODS: Consecutive group of NVAMD patients who were treated in a single 3(rd) referral center with bevacizumab using a loading dosage of 3 monthly injections followed by variable dosing for at least 48 months were retrospectively evaluated. Genotyping was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorescein Angiography

Share to Fundus Oculi

Share to Intravitreal Injections

Share to Macular Degeneration

Share to Retinal Neovascularization

Share to Tomography, Optical Coherence

Source

Open in PubMed Open full text

Identifiers

PMID: 25881145
DOI: 10.1186/s12886-015-0019-x
PMCID: PMC4404564

Genes

CFH
HTRA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome.PMID 25881145Read ↗

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles.Semantic proximity Read ↗

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.Semantic proximity Read ↗

Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.Semantic proximity Read ↗

Eighteen-Month Real-World Outcomes of Intravitreal Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A UK Single- Centre ExperienceSemantic proximity Read ↗

Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study.Semantic proximity Read ↗

Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Semantic proximity Read ↗

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.Semantic proximity Read ↗

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

The Moorfields AMD Database Report 2 - Fellow Eye Involvement with Neovascular Age-related Macular DegenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.